{"id":"NCT02031432","sponsor":"Tris Pharma, Inc.","briefTitle":"CORAL XT - Open-label Extension Trial of the CORAL Trial","officialTitle":"An Open-label, Multi-site Trial to Describe the Safety and Tolerability of Oral Cebranopadol Administered for 26 Weeks in Subjects With Cancer-related Pain Who Have Completed Treatment in the KF6005/07 Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-18","primaryCompletion":"2016-04","completion":"2016-05-03","firstPosted":"2014-01-09","resultsPosted":"2020-01-18","lastUpdate":"2021-07-15"},"enrollment":76,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pain","Neoplasms","Chronic Pain"],"interventions":[{"type":"DRUG","name":"Cebranopadol","otherNames":["GRT6005"]}],"arms":[{"label":"Cebranopadol","type":"EXPERIMENTAL"}],"summary":"The purpose of this trial was to find out how well cebranopadol is tolerated and how often, and which, adverse reactions occur when it is taken every day for a longer period of time. In addition, information was collected how cebranopadol affects pain and well-being in patients suffering from cancer-related pain.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Event (TEAEs)","timeFrame":"Up to 28 weeks (26 weeks of cebranopadol treatment and 2 weeks follow up after the last dose)","effectByArm":[{"arm":"Cebranopadol","deltaMin":64,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":22,"countries":["Austria","Belgium","Bulgaria","Denmark","Germany","Hungary","Poland","Romania","Serbia","Slovakia"]},"refs":{"pmids":["31152783"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":76},"commonTop":["Asthenia","Decreased appetite","Nausea","Constipation","Fatigue"]}}